2. Others
  3. Others
  4. P7C3-A20

P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment.

For research use only. We do not sell to patients.

P7C3-A20 Chemical Structure

P7C3-A20 Chemical Structure

CAS No. : 1235481-90-9

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent
10 mM * 1 mL in DMSO
ready for reconstitution
 USD 74 In-stock
Solution
10 mM * 1 mL in DMSO USD 74 In-stock
Solid
5 mg USD 66 In-stock
10 mg USD 99 In-stock
25 mg USD 125 In-stock
50 mg USD 209 In-stock
100 mg USD 319 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of P7C3-A20:

P7C3-A20 Related Antibodies

Top Publications Citing Use of Products

    P7C3-A20 purchased from MedChemExpress. Usage Cited in: Neuroscience. 2020 Aug 10;441:197-208.  [Abstract]

    P7C3-A20 alleviates HI injury. MAP-2 and MBP protein levels 7 days after HI in sham, HIE, and HIE + P7C3-A20 5 and 10 mg/kg groups.

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    P7C3-A20 is a derivative of P7C3 with potent proneurogenic and neuroprotective activity. P7C3-A20 exerts an antidepressant-like effect. P7C3-A20 can cross the blood-brain barrier and therefore has the potential for brain injury treatment[1][2][3].

    In Vitro

    P7C3-A20 (10-100 μM; 8 hours; PC12 cells) treatment alleviates oxygen-glucose deprivation (OGD)-induced cytotoxicity in PC12 cells[1].
    P7C3-A20 (40-100 μM; 8 hours; PC12 cells) treatment alleviates OGD-induced apoptosis in PC12 cells[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    P7C3-A20 Related Antibodies

    Cell Viability Assay[1]

    Cell Line: PC12 cells
    Concentration: 10 μM, 20 μM, 40 μM, 60 μM, 80 μM, 100 μM
    Incubation Time: 8 hours
    Result: Alleviated oxygen-glucose deprivation (OGD)-induced cytotoxicity in PC12 cells.

    Apoptosis Analysis[1]

    Cell Line: PC12 cells
    Concentration: 40 μM, 60 μM, 80 μM, 100 μM
    Incubation Time: 8 hours
    Result: Alleviated oxygen-glucose deprivation (OGD)-induced apoptosis in PC12 cells.
    In Vivo

    P7C3-A20 (5-10 mg/kg; intraperitoneal injection; daily; for 7 days; Sprague-Dawley rats) treatment reduces infarct volume; reverses cell loss in the cortex and hippocampus and improves motor function without causing neurotoxicity in HI model rats. P7C3-A20 prevents HI-induced neuronal injury via activation of the PI3K/AKT/GSK3β signaling pathway[1].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Sprague-Dawley rats (200-250 g) induced hypoxic-ischemic (HI) injury [1]
    Dosage: 5 mg/kg, 10 mg/kg
    Administration: Intraperitoneal injection; daily; for 7 days
    Result: Reduced infarct volume; reversed cell loss in the cortex and hippocampus and improved motor function without causing neurotoxicity.
    Molecular Weight

    506.21

    Formula

    C22H19Br2FN2O
    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    FC(CNC1=CC(OC)=CC=C1)CN2C3=CC=C(Br)C=C3C4=CC(Br)=CC=C24
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 2 years
    -20°C 1 year
    Solvent & Solubility
    In Vitro: 

    DMSO : ≥ 100 mg/mL (197.55 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.9755 mL 9.8773 mL 19.7546 mL
    5 mM 0.3951 mL 1.9755 mL 3.9509 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 3.85 mg/mL (7.61 mM); Clear solution

      This protocol yields a clear solution of ≥ 3.85 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (38.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (4.94 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 98.97%

    COA (247 KB) LCMS (303 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.9755 mL 9.8773 mL 19.7546 mL 49.3866 mL
    5 mM 0.3951 mL 1.9755 mL 3.9509 mL 9.8773 mL
    10 mM 0.1975 mL 0.9877 mL 1.9755 mL 4.9387 mL
    15 mM 0.1317 mL 0.6585 mL 1.3170 mL 3.2924 mL
    20 mM 0.0988 mL 0.4939 mL 0.9877 mL 2.4693 mL
    25 mM 0.0790 mL 0.3951 mL 0.7902 mL 1.9755 mL
    30 mM 0.0658 mL 0.3292 mL 0.6585 mL 1.6462 mL
    40 mM 0.0494 mL 0.2469 mL 0.4939 mL 1.2347 mL
    50 mM 0.0395 mL 0.1975 mL 0.3951 mL 0.9877 mL
    60 mM 0.0329 mL 0.1646 mL 0.3292 mL 0.8231 mL
    80 mM 0.0247 mL 0.1235 mL 0.2469 mL 0.6173 mL
    100 mM 0.0198 mL 0.0988 mL 0.1975 mL 0.4939 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    P7C3-A20 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    P7C3-A201235481-90-9OthersHypoxic-ischemicneuroprotectiveinfarctPI3KAKTGSK3βBBBantidepressantInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Salutation

    Applicant Name *

    		 

    Email Address *

    Phone Number *

    		 

    Organization Name *

    Department *

    		 

    Requested quantity *

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    P7C3-A20
    Cat. No.:
    HY-15978
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.